The twice-yearly injectable drug’s potential could be compromised by the Trump administration’s dramatic cuts to HIV-prevention infrastructure in the U.S.

https://www.nbcnews.com/health/health-news/fda-hiv-prevention-drug-prep-lenacapavir-rcna208387